Combining Tazemetostat with CAR T Cell Therapy for B-cell Lymphomas
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
This study is testing if taking a new pill called tazemetostat before and after CAR T cell therapy can help people with certain types of B-cell lymphomas feel better and improve their treatment outcomes.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Drugs / interventions | CAR T, CART, chemotherapy |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05934838 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the feasibility and safety of administering tazemetostat followed by CAR T cell therapy in patients with previously treated diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Participants will take tazemetostat orally for a period before and after receiving CAR T cell infusion, with the aim of enhancing the effectiveness of the CAR T cells in targeting lymphoma cells. The study will monitor participants for up to five years to assess outcomes and safety.
Who should consider this trial
Good fit: Ideal candidates include individuals with confirmed diagnoses of DLBCL, FL, or MCL who have received at least one prior therapy and are eligible for CAR T cell treatment.
Not a fit: Patients with active viral infections, other active cancers, or those unable to take oral medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment outcomes for patients with B-cell lymphomas.
How similar studies have performed: While the combination of tazemetostat and CAR T cell therapy is a novel approach, similar studies have shown promise in enhancing CAR T cell effectiveness in hematological malignancies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of DLBCL, FL, or MCL * Eligible to receive standard of care CAR T cells * Have received at least 1 prior therapies Exclusion Criteria: * Active viral infection with HIV or hepatitis type B or C * Active, uncontrolled systemic fungal, bacterial or viral infection * Active treatment for another cancer * Pregnant or breastfeeding * Unable to take oral medication * Certain significant past medical history, such recent stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias
Where this trial is running
New York, New York
- Weill Cornell Medicine/NewYork-Presbyterian Hospital — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Samuel Yamshon, M.D. — Weill Medical College of Cornell University
- Study coordinator: Nicole Santos
- Email: nis7058@med.cornell.edu
- Phone: 646-962-6827
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.